Housemeda - Company finances
- The company has not submitted financial data for these years: 2021.
|
EUR
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|
|
Financial data
|
||||
| Sales revenue | 22,912 | 38,975 | 36,695 | 46,376 |
| Profit before tax | -4,563 | 3,814 | 9,446 | 9,948 |
| Net profit | -4,563 | 3,584 | 8,930 | 9,304 |
| Equity | 9,138 | 10,476 | 13,003 | 22,307 |
| Liabilities | 8,344 | 8,084 | 5,839 | 5,020 |
| Non-current assets | 0 | 12,990 | 12,990 | 12,990 |
| Current assets | 17,482 | 5,570 | 5,852 | 14,337 |
| Total assets | 17,482 | 18,560 | 18,842 | 27,327 |
|
Taxes paid
|
||||
| STI taxes | - | 2,554 | 3,979 | 4,481 |
|
Financial indicators
|
||||
| Revenue change y/y | - | +70.1% | -5.8% | +26.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -26.1% | 19.3% | 47.4% | 34.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -49.9% | 34.2% | 68.7% | 41.7% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -19.9% | 9.2% | 24.3% | 20.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -19.9% | 9.8% | 25.7% | 21.5% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.9 | 0.8 | 0.4 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 22,912 | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Housemeda - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-05-02 | 2024-03-31 | 1.45 |
| 2022-07-25 | 2023-04-30 | 1.45 |
| 2022-04-25 | 2022-07-24 | 57.69 |
| 2022-04-19 | 2022-04-24 | 57.52 |
| 2022-03-16 | 2022-03-24 | 20.61 |
| 2022-02-17 | 2022-02-22 | 20.85 |
| 2022-01-31 | 2022-02-16 | 0.24 |
| 2022-01-18 | 2022-01-26 | 20.36 |
| 2021-12-16 | 2021-12-26 | 20.36 |
| 2021-11-16 | 2021-11-23 | 20.70 |
| 2021-11-08 | 2021-11-15 | 0.34 |
| 2021-10-18 | 2021-10-24 | 40.72 |
| 2021-09-16 | 2021-10-17 | 20.36 |
Housemeda - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-06-30 | 2026-06-30 | 7.82 |
| 2026-06-18 | 2026-06-29 | 21.7 |
| 2025-08-02 | 2025-08-25 | 11.4 |
| 2025-07-31 | 2025-08-01 | 1163.75 |
| 2025-07-27 | 2025-07-30 | 1162.0 |
| 2025-07-24 | 2025-07-26 | 1312.0 |
| 2025-07-09 | 2025-07-20 | 467.99 |
| 2025-07-02 | 2025-07-08 | 550.85 |
| 2025-07-01 | 2025-07-01 | 1103.52 |
| 2025-06-28 | 2025-06-30 | 1100.97 |
| 2025-06-19 | 2025-06-27 | 552.97 |
| 2025-06-02 | 2025-06-18 | 0.67 |
| 2025-05-01 | 2025-06-01 | 0.47 |
| 2025-04-28 | 2025-04-30 | 345.02 |
| 2025-03-03 | 2025-04-27 | 0.02 |
| 2025-03-02 | 2025-03-02 | 24.65 |
| 2025-03-01 | 2025-03-01 | 650.0 |
| 2025-02-28 | 2025-02-28 | 674.0 |
| 2025-02-20 | 2025-02-27 | 24.0 |
| 2024-12-30 | 2024-12-31 | 343.67 |
| 2024-11-01 | 2024-11-26 | 3.67 |
| 2024-10-10 | 2024-10-31 | 244.02 |
| 2024-10-01 | 2024-10-09 | 865.55 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Housemeda, MB (code 305243048) is a Lithuanian small partnership engaged in new construction. In 2025, the company generated revenue of EUR 46.4K, up 26.4% year on year and 19.0% over two years. Net profit reached EUR 9.3K, slightly above the EUR 8.9K earned in 2024 and well ahead of EUR 3.6K in 2023, showing a clear improvement in earnings over the three-year period. Profit margin stood at 20.1% in 2025, after 24.3% in 2024 and 9.2% in 2023, indicating that profitability remained solid despite some margin normalization. The balance sheet also strengthened: total assets increased from EUR 18.6K in 2023 and EUR 18.8K in 2024 to EUR 27.3K in 2025. Equity rose to EUR 22.3K, while liabilities remained low at EUR 5.0K. The latest ratios point to a strong capital structure, with an equity ratio of 81.6%, debt-to-equity of 0.23, asset turnover of 1.70x, ROE of 41.7% and ROA of 34.0%.